MetLife, Inc. reports results for the quarter ended June 30 - Earnings Summary
MetLife, Inc. reports results for the quarter ended June 30 - Earnings Summary
MetLife, Inc. MET.N reported quarterly adjusted earnings of $2.43 per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $2.02. The mean expectation of sixteen analysts for the quarter was for earnings of $2.29 per share. Wall Street expected results to range from $2.20 to $2.40 per share.
Revenue rose 6.4% to $19.08 billion from a year ago; analysts expected $19.71 billion.
MetLife, Inc.'s reported EPS for the quarter was $1.09.
The company reported quarterly net income of $705 million.
MetLife, Inc. shares had risen by 13.6% this quarter and gained 21.8% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 5.9% in the last three months.
In the last 30 days, ten analysts negatively revised earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy," 6 "hold" and no "sell" or "strong sell." The average consensus recommendation for the life & health insurance peer group is also "buy"
Wall Street's median 12-month price target for MetLife, Inc. is $98.50, about 2.4% above its last closing price of $96.13
This summary was machine generated from LSEG data August 5 at 09:41 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Jun. 30 2026 | 2.29 | 2.43 | Beat |
Mar. 31 2026 | 2.27 | 2.42 | Beat |
Dec. 31 2025 | 2.34 | 2.58 | Beat |
Sep. 30 2025 | 2.32 | 2.37 | Beat |
Recent news on MetLife
See all newsMedia: Prudential Mexico, Brazil units draw interest from MetLife, CNP - Bloomberg News
US RESEARCH ROUNDUP-Danaher Corporation, Illumina, Reliance
Brief: Metlife Full-Year 2026 Guidance For Variable Investment Income About $1.60 Billion Pre-Tax
U.S. RESEARCH ROUNDUP-Accendra Health, Celestica, Sionna Therapeutics
MetLife, Inc. reports results for the quarter ended June 30 - Earnings Summary